Discover how AI-driven pharmacovigilance uses machine learning, NLP, and real‑world data to move drug safety from passive reporting to proactive, intelligent risk management—enhancing signal detection, case processing, and patient-centric risk mitigation.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Discover how artificial intelligence and machine learning are reshaping pharmacovigilance, from automated case intake and triage to advanced signal detection using EHRs, claims data, and real-world evidence to improve drug safety and ADR prevention.
Discover how NTRX-07, a first-in-class small molecule targeting microglial activity, offers a novel immunology-based strategy for Alzheimer’s disease by reducing neuroinflammation, enhancing amyloid-β clearance, and promoting neuroprotective repair pathways.
Discover how tirzepatide, a dual GIP and GLP-1 receptor agonist, delivers powerful glucose control and bariatric-level weight loss through smart peptide engineering, albumin binding, and protease resistance in modern metabolic medicine.
Discover how AI-powered pharmacovigilance uses machine learning, NLP, and real-time data to transform drug safety, accelerate signal detection, and improve adverse event risk assessment for life science companies.
Discover why KRAS was historically labeled “undruggable,” how covalent KRAS G12C inhibitors like sotorasib and adagrasib overcame structural challenges, and what this breakthrough means for treating KRAS-mutant cancers such as NSCLC, colorectal, and pancreatic tumors.
Learn how tirzepatide, a once‑weekly dual GIP/GLP‑1 receptor agonist, improves blood sugar control and drives significant weight loss. Explore its dual incretin mechanism, SURPASS and SURMOUNT clinical trial results, and its role in treating type 2 diabetes and obesity.
Discover why tirzepatide is the most talked‑about peptide drug in metabolic medicine. Learn how its dual GIP/GLP‑1 agonism outperforms traditional GLP‑1 therapies in type 2 diabetes, obesity, weight loss, and metabolic remodeling.
Discover how AI‑driven pharmacovigilance is reshaping drug safety—from automated case intake and adverse event detection to real‑time signal detection across EHRs, claims, social media, and wearables—plus the new risks and responsibilities for regulators, pharma companies, and patients.